Diseases /
Multiple Myeloma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) [1]
Clinical Trials
There are 115 clinical trials for multiple myeloma, of which 93 are open and 22 are completed or closed. Of the trials that contain multiple myeloma as an inclusion criterion, 41 are phase 1 (31 open), 21 are phase 1/phase 2 (14 open), 44 are phase 2 (39 open), 5 are phase 3 (5 open), and 4 are no phase specified (4 open).
IGH, FGFR3, and ABL1 are the most frequent gene inclusion criteria for multiple myeloma clinical trials [3].
Cyclophosphamide, fludarabine, and dexamethasone are the most common interventions in multiple myeloma clinical trials.
Significant Genes in Multiple Myeloma
ABL1 +
ABL1 is an inclusion eligibility criterion in 21 clinical trials for multiple myeloma, of which 19 are open and 2 are closed. Of the trials that contain ABL1 status and multiple myeloma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 13 are phase 2 (13 open), and 2 are no phase specified (2 open) [3].
Cyclophosphamide, fludarabine, and total-body irradiation are the most frequent therapies in multiple myeloma trials with ABL1 mutations as inclusion criteria [3].
AFF1 +
AFF1 is an inclusion eligibility criterion in 15 clinical trials for multiple myeloma, of which 13 are open and 2 are closed. Of the trials that contain AFF1 status and multiple myeloma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), 8 are phase 2 (8 open), and 2 are no phase specified (2 open) [3].
Cyclophosphamide, fludarabine, and total-body irradiation are the most frequent therapies in multiple myeloma trials with AFF1 mutations as inclusion criteria [3].
AKT1 +
AKT1 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
Vismodegib, pertuzumab, and nivolumab are the most frequent therapies in multiple myeloma trials with AKT1 mutations as inclusion criteria [3].
AKT2 +
AKT2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with AKT2 mutations as inclusion criteria [3].
AKT3 +
AKT3 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with AKT3 mutations as inclusion criteria [3].
ALK +
ALK is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain ALK status and multiple myeloma as inclusion criteria, 3 are phase 2 (3 open) [3].
Nivolumab, palbociclib, and dasatinib are the most frequent therapies in multiple myeloma trials with ALK mutations as inclusion criteria [3].
ARAF +
ARAF is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
Raf/mek serine/threonine kinase inhibitor ro5126766 and everolimus are the most frequent therapies in multiple myeloma trials with ARAF mutations as inclusion criteria [3].
ASXL1 +
ASXL1 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain ASXL1 status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
Allogeneic hematopoietic stem cell transplantation, antineoplastic immune cell, and autologous hematopoietic stem cell transplatation are the most frequent therapies in multiple myeloma trials with ASXL1 mutations as inclusion criteria [3].
ATM +
ATM is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain ATM status and multiple myeloma as inclusion criteria, 3 are phase 2 (3 open) [3].
Nivolumab, vemurafenib, and trastuzumab are the most frequent therapies in multiple myeloma trials with ATM mutations as inclusion criteria [3].
ATR +
ATR is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with ATR mutations as inclusion criteria [3].
BARD1 +
BARD1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with BARD1 mutations as inclusion criteria [3].
BCL2 +
BCL2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains BCL2 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
Bet inhibitor gsk525762 is the most frequent therapy in multiple myeloma trials with BCL2 mutations as inclusion criteria [3].
BCL6 +
BCL6 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
Bet inhibitor gsk525762 is the most frequent therapy in multiple myeloma trials with BCL6 mutations as inclusion criteria [3].
BCR +
BCR is an inclusion eligibility criterion in 20 clinical trials for multiple myeloma, of which 18 are open and 2 are closed. Of the trials that contain BCR status and multiple myeloma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 12 are phase 2 (12 open), and 2 are no phase specified (2 open) [3].
Cyclophosphamide, fludarabine, and total-body irradiation are the most frequent therapies in multiple myeloma trials with BCR mutations as inclusion criteria [3].
BIRC3 +
BIRC3 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Mln9708, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in multiple myeloma trials with BIRC3 mutations as inclusion criteria [3].
BRAF +
BRAF is an inclusion eligibility criterion in 11 clinical trials for multiple myeloma, of which 9 are open and 2 are closed. Of the trials that contain BRAF status and multiple myeloma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 8 are phase 2 (6 open) [3].
Vemurafenib, trametinib, and dabrafenib are the most frequent therapies in multiple myeloma trials with BRAF mutations as inclusion criteria [3].
BRCA1 +
BRCA1 is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain BRCA1 status and multiple myeloma as inclusion criteria, 3 are phase 2 (3 open) [3].
Nivolumab, palbociclib, and dasatinib are the most frequent therapies in multiple myeloma trials with BRCA1 mutations as inclusion criteria [3].
BRCA2 +
BRCA2 is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain BRCA2 status and multiple myeloma as inclusion criteria, 3 are phase 2 (3 open) [3].
Nivolumab, palbociclib, and dasatinib are the most frequent therapies in multiple myeloma trials with BRCA2 mutations as inclusion criteria [3].
BRIP1 +
BRIP1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with BRIP1 mutations as inclusion criteria [3].
CALR +
CALR is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CALR status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Allogeneic hematopoietic stem cell transplantation, busulfan, and cyclophosphamide are the most frequent therapies in multiple myeloma trials with CALR mutations as inclusion criteria [3].
CBFB +
CBFB is an inclusion eligibility criterion in 5 clinical trials for multiple myeloma, of which 3 are open and 2 are closed. Of the trials that contain CBFB status and multiple myeloma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), 1 is phase 2 (1 open), and 1 is no phase specified (1 open) [3].
Cyclophosphamide, fludarabine, and total-body irradiation are the most frequent therapies in multiple myeloma trials with CBFB mutations as inclusion criteria [3].
CCND1 +
CCND1 is an inclusion eligibility criterion in 8 clinical trials for multiple myeloma, of which 6 are open and 2 are closed. Of the trials that contain CCND1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (1 open), 4 are phase 2 (4 open), and 1 is phase 3 (1 open) [3].
Ixazomib, erdafitinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with CCND1 mutations as inclusion criteria [3].
CCND2 +
CCND2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CCND2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Azd4547, erdafitinib, and trastuzumab emtansine are the most frequent therapies in multiple myeloma trials with CCND2 mutations as inclusion criteria [3].
CCND3 +
CCND3 is an inclusion eligibility criterion in 4 clinical trials for multiple myeloma, of which 4 are open and 0 are closed. Of the trials that contain CCND3 status and multiple myeloma as inclusion criteria, 3 are phase 2 (3 open) and 1 is phase 3 (1 open) [3].
Placebo, ixazomib, and azd4547 are the most frequent therapies in multiple myeloma trials with CCND3 mutations as inclusion criteria [3].
CDK4 +
CDK4 is an inclusion eligibility criterion in 4 clinical trials for multiple myeloma, of which 4 are open and 0 are closed. Of the trials that contain CDK4 status and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [3].
Cobimetinib, sunitinib, and nivolumab are the most frequent therapies in multiple myeloma trials with CDK4 mutations as inclusion criteria [3].
CDK6 +
CDK6 is an inclusion eligibility criterion in 4 clinical trials for multiple myeloma, of which 4 are open and 0 are closed. Of the trials that contain CDK6 status and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [3].
Cobimetinib, sunitinib, and nivolumab are the most frequent therapies in multiple myeloma trials with CDK6 mutations as inclusion criteria [3].
CDKN2A +
CDKN2A is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
Olaparib, vemurafenib, and cobimetinib are the most frequent therapies in multiple myeloma trials with CDKN2A mutations as inclusion criteria [3].
CDKN2C +
CDKN2C is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2C status and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
Abemaciclib, cobimetinib, and daratumumab are the most frequent therapies in multiple myeloma trials with CDKN2C mutations as inclusion criteria [3].
CHEK1 +
CHEK1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with CHEK1 mutations as inclusion criteria [3].
CHEK2 +
CHEK2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with CHEK2 mutations as inclusion criteria [3].
CRKL +
CRKL is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
Raf/mek serine/threonine kinase inhibitor ro5126766 and everolimus are the most frequent therapies in multiple myeloma trials with CRKL mutations as inclusion criteria [3].
CSF1R +
CSF1R is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain CSF1R status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
Olaparib, vemurafenib, and cobimetinib are the most frequent therapies in multiple myeloma trials with CSF1R mutations as inclusion criteria [3].
DDR2 +
DDR2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Azd4547, erdafitinib, and trastuzumab emtansine are the most frequent therapies in multiple myeloma trials with DDR2 mutations as inclusion criteria [3].
DEK +
DEK is an inclusion eligibility criterion in 16 clinical trials for multiple myeloma, of which 14 are open and 2 are closed. Of the trials that contain DEK status and multiple myeloma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), 9 are phase 2 (9 open), and 2 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in multiple myeloma trials with DEK mutations as inclusion criteria [3].
EGFR +
EGFR is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain EGFR status and multiple myeloma as inclusion criteria, 3 are phase 2 (3 open) [3].
Nivolumab, palbociclib, and dasatinib are the most frequent therapies in multiple myeloma trials with EGFR mutations as inclusion criteria [3].
ELL +
ELL is an inclusion eligibility criterion in 15 clinical trials for multiple myeloma, of which 13 are open and 2 are closed. Of the trials that contain ELL status and multiple myeloma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), 8 are phase 2 (8 open), and 2 are no phase specified (2 open) [3].
Cyclophosphamide, fludarabine, and total-body irradiation are the most frequent therapies in multiple myeloma trials with ELL mutations as inclusion criteria [3].
EPHA2 +
EPHA2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Cetuximab, cobimetinib, and crizotinib are the most frequent therapies in multiple myeloma trials with EPHA2 mutations as inclusion criteria [3].
ERBB2 +
ERBB2 is an inclusion eligibility criterion in 5 clinical trials for multiple myeloma, of which 5 are open and 0 are closed. Of the trials that contain ERBB2 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 3 are phase 2 (3 open) [3].
Pertuzumab, nivolumab, and dasatinib are the most frequent therapies in multiple myeloma trials with ERBB2 mutations as inclusion criteria [3].
EZH2 +
EZH2 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 1 is open and 1 is closed. Of the trials that contain EZH2 status and multiple myeloma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
Histone-lysine n-methyltransferase ezh2 inhibitor gsk2816126, allogeneic hematopoietic stem cell transplantation, and busulfan are the most frequent therapies in multiple myeloma trials with EZH2 mutations as inclusion criteria [3].
FANCA +
FANCA is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with FANCA mutations as inclusion criteria [3].
FANCB +
FANCB is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with FANCB mutations as inclusion criteria [3].
FANCC +
FANCC is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with FANCC mutations as inclusion criteria [3].
FANCD2 +
FANCD2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with FANCD2 mutations as inclusion criteria [3].
FANCE +
FANCE is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with FANCE mutations as inclusion criteria [3].
FANCF +
FANCF is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with FANCF mutations as inclusion criteria [3].
FANCG +
FANCG is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with FANCG mutations as inclusion criteria [3].
FANCI +
FANCI is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with FANCI mutations as inclusion criteria [3].
FANCL +
FANCL is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with FANCL mutations as inclusion criteria [3].
FANCM +
FANCM is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with FANCM mutations as inclusion criteria [3].
FBXW7 +
FBXW7 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with FBXW7 mutations as inclusion criteria [3].
FGF1 +
FGF1 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF1 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF1 mutations as inclusion criteria [3].
FGF10 +
FGF10 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF10 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF10 mutations as inclusion criteria [3].
FGF11 +
FGF11 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF11 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF11 mutations as inclusion criteria [3].
FGF12 +
FGF12 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF12 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF12 mutations as inclusion criteria [3].
FGF13 +
FGF13 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF13 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF13 mutations as inclusion criteria [3].
FGF14 +
FGF14 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF14 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF14 mutations as inclusion criteria [3].
FGF16 +
FGF16 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF16 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF16 mutations as inclusion criteria [3].
FGF17 +
FGF17 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF17 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF17 mutations as inclusion criteria [3].
FGF18 +
FGF18 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF18 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF18 mutations as inclusion criteria [3].
FGF19 +
FGF19 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF19 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF19 mutations as inclusion criteria [3].
FGF2 +
FGF2 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF2 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF2 mutations as inclusion criteria [3].
FGF20 +
FGF20 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF20 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF20 mutations as inclusion criteria [3].
FGF21 +
FGF21 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF21 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF21 mutations as inclusion criteria [3].
FGF22 +
FGF22 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF22 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF22 mutations as inclusion criteria [3].
FGF23 +
FGF23 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF23 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF23 mutations as inclusion criteria [3].
FGF3 +
FGF3 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF3 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF3 mutations as inclusion criteria [3].
FGF4 +
FGF4 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF4 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF4 mutations as inclusion criteria [3].
FGF5 +
FGF5 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF5 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF5 mutations as inclusion criteria [3].
FGF6 +
FGF6 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF6 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF6 mutations as inclusion criteria [3].
FGF7 +
FGF7 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF7 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF7 mutations as inclusion criteria [3].
FGF8 +
FGF8 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF8 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF8 mutations as inclusion criteria [3].
FGF9 +
FGF9 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGF9 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
Anti-pd-1 monoclonal antibody mga012, fgfr inhibitor tas-120, and cisplatin are the most frequent therapies in multiple myeloma trials with FGF9 mutations as inclusion criteria [3].
FGFR1 +
FGFR1 is an inclusion eligibility criterion in 5 clinical trials for multiple myeloma, of which 5 are open and 0 are closed. Of the trials that contain FGFR1 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 3 are phase 2 (3 open) [3].
Vismodegib, sunitinib, and nivolumab are the most frequent therapies in multiple myeloma trials with FGFR1 mutations as inclusion criteria [3].
FGFR2 +
FGFR2 is an inclusion eligibility criterion in 5 clinical trials for multiple myeloma, of which 5 are open and 0 are closed. Of the trials that contain FGFR2 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 3 are phase 2 (3 open) [3].
Vismodegib, sunitinib, and nivolumab are the most frequent therapies in multiple myeloma trials with FGFR2 mutations as inclusion criteria [3].
FGFR3 +
FGFR3 is an inclusion eligibility criterion in 25 clinical trials for multiple myeloma, of which 21 are open and 4 are closed. Of the trials that contain FGFR3 status and multiple myeloma as inclusion criteria, 3 are phase 1 (2 open), 5 are phase 1/phase 2 (4 open), and 17 are phase 2 (15 open) [3].
Dexamethasone, melphalan, and fludarabine are the most frequent therapies in multiple myeloma trials with FGFR3 mutations as inclusion criteria [3].
FGFR4 +
FGFR4 is an inclusion eligibility criterion in 4 clinical trials for multiple myeloma, of which 4 are open and 0 are closed. Of the trials that contain FGFR4 status and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (2 open) [3].
Azd4547, anti-pd-1 monoclonal antibody mga012, and trastuzumab emtansine are the most frequent therapies in multiple myeloma trials with FGFR4 mutations as inclusion criteria [3].
FLCN +
FLCN is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FLCN status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with FLCN mutations as inclusion criteria [3].
FLT1 +
FLT1 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FLT1 status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
Olaparib, vemurafenib, and cobimetinib are the most frequent therapies in multiple myeloma trials with FLT1 mutations as inclusion criteria [3].
FLT3 +
FLT3 is an inclusion eligibility criterion in 21 clinical trials for multiple myeloma, of which 17 are open and 4 are closed. Of the trials that contain FLT3 status and multiple myeloma as inclusion criteria, 5 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), 13 are phase 2 (12 open), and 2 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in multiple myeloma trials with FLT3 mutations as inclusion criteria [3].
FLT4 +
FLT4 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FLT4 status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
Olaparib, vemurafenib, and cobimetinib are the most frequent therapies in multiple myeloma trials with FLT4 mutations as inclusion criteria [3].
FYN +
FYN is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FYN status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Cetuximab, cobimetinib, and crizotinib are the most frequent therapies in multiple myeloma trials with FYN mutations as inclusion criteria [3].
GNA11 +
GNA11 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains GNA11 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Azd4547, erdafitinib, and trastuzumab emtansine are the most frequent therapies in multiple myeloma trials with GNA11 mutations as inclusion criteria [3].
GNAQ +
GNAQ is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains GNAQ status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Azd4547, erdafitinib, and trastuzumab emtansine are the most frequent therapies in multiple myeloma trials with GNAQ mutations as inclusion criteria [3].
HRAS +
HRAS is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain HRAS status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
Antineoplastic immune cell, raf/mek serine/threonine kinase inhibitor ro5126766, and abemaciclib are the most frequent therapies in multiple myeloma trials with HRAS mutations as inclusion criteria [3].
IDH1 +
IDH1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Allogeneic hematopoietic stem cell transplantation, busulfan, and cyclophosphamide are the most frequent therapies in multiple myeloma trials with IDH1 mutations as inclusion criteria [3].
IDH2 +
IDH2 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain IDH2 status and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].
Abemaciclib, allogeneic hematopoietic stem cell transplantation, and busulfan are the most frequent therapies in multiple myeloma trials with IDH2 mutations as inclusion criteria [3].
IGH +
IGH is an inclusion eligibility criterion in 29 clinical trials for multiple myeloma, of which 21 are open and 8 are closed. Of the trials that contain IGH status and multiple myeloma as inclusion criteria, 6 are phase 1 (2 open), 6 are phase 1/phase 2 (4 open), 16 are phase 2 (14 open), and 1 is phase 3 (1 open) [3].
Dexamethasone, lenalidomide, and melphalan are the most frequent therapies in multiple myeloma trials with IGH mutations as inclusion criteria [3].
IKZF1 +
IKZF1 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain IKZF1 status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most frequent therapies in multiple myeloma trials with IKZF1 mutations as inclusion criteria [3].
JAK2 +
JAK2 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain JAK2 status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
Allogeneic hematopoietic stem cell transplantation, antineoplastic immune cell, and autologous hematopoietic stem cell transplatation are the most frequent therapies in multiple myeloma trials with JAK2 mutations as inclusion criteria [3].
KDR +
KDR is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain KDR status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
Olaparib, vemurafenib, and cobimetinib are the most frequent therapies in multiple myeloma trials with KDR mutations as inclusion criteria [3].
KIT +
KIT is an inclusion eligibility criterion in 9 clinical trials for multiple myeloma, of which 7 are open and 2 are closed. Of the trials that contain KIT status and multiple myeloma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), 5 are phase 2 (5 open), and 1 is no phase specified (1 open) [3].
Fludarabine, cyclophosphamide, and melphalan are the most frequent therapies in multiple myeloma trials with KIT mutations as inclusion criteria [3].
KMT2A +
KMT2A is an inclusion eligibility criterion in 16 clinical trials for multiple myeloma, of which 14 are open and 2 are closed. Of the trials that contain KMT2A status and multiple myeloma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), 9 are phase 2 (9 open), and 2 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in multiple myeloma trials with KMT2A mutations as inclusion criteria [3].
KRAS +
KRAS is an inclusion eligibility criterion in 5 clinical trials for multiple myeloma, of which 4 are open and 1 is closed. Of the trials that contain KRAS status and multiple myeloma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [3].
Trametinib, antineoplastic immune cell, and raf/mek serine/threonine kinase inhibitor ro5126766 are the most frequent therapies in multiple myeloma trials with KRAS mutations as inclusion criteria [3].
LCK +
LCK is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains LCK status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Cetuximab, cobimetinib, and crizotinib are the most frequent therapies in multiple myeloma trials with LCK mutations as inclusion criteria [3].
LYN +
LYN is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains LYN status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Cetuximab, cobimetinib, and crizotinib are the most frequent therapies in multiple myeloma trials with LYN mutations as inclusion criteria [3].
MAF +
MAF is an inclusion eligibility criterion in 12 clinical trials for multiple myeloma, of which 9 are open and 3 are closed. Of the trials that contain MAF status and multiple myeloma as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 7 are phase 2 (5 open) [3].
Dexamethasone, fludarabine, and lenalidomide are the most frequent therapies in multiple myeloma trials with MAF mutations as inclusion criteria [3].
MAFB +
MAFB is an inclusion eligibility criterion in 6 clinical trials for multiple myeloma, of which 5 are open and 1 is closed. Of the trials that contain MAFB status and multiple myeloma as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
Allogeneic hematopoietic stem cell transplantation, bortezomib, and dexamethasone are the most frequent therapies in multiple myeloma trials with MAFB mutations as inclusion criteria [3].
MAP2K1 +
MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
Raf/mek serine/threonine kinase inhibitor ro5126766 and everolimus are the most frequent therapies in multiple myeloma trials with MAP2K1 mutations as inclusion criteria [3].
MAP2K2 +
MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
Raf/mek serine/threonine kinase inhibitor ro5126766 and everolimus are the most frequent therapies in multiple myeloma trials with MAP2K2 mutations as inclusion criteria [3].
MAP2K4 +
MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
Raf/mek serine/threonine kinase inhibitor ro5126766 and everolimus are the most frequent therapies in multiple myeloma trials with MAP2K4 mutations as inclusion criteria [3].
MAP3K1 +
MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
Raf/mek serine/threonine kinase inhibitor ro5126766 and everolimus are the most frequent therapies in multiple myeloma trials with MAP3K1 mutations as inclusion criteria [3].
MAPK1 +
MAPK1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [3].
Raf/mek serine/threonine kinase inhibitor ro5126766 and everolimus are the most frequent therapies in multiple myeloma trials with MAPK1 mutations as inclusion criteria [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with MCPH1 mutations as inclusion criteria [3].
MDM2 +
MDM2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 0 are open and 1 is closed. Of the trial that contains MDM2 status and multiple myeloma as inclusion criteria, 1 is phase 1 (0 open) [3].
Mdm2 inhibitor amg-232 is the most frequent therapy in multiple myeloma trials with MDM2 mutations as inclusion criteria [3].
MECOM +
MECOM is an inclusion eligibility criterion in 17 clinical trials for multiple myeloma, of which 15 are open and 2 are closed. Of the trials that contain MECOM status and multiple myeloma as inclusion criteria, 5 are phase 1 (4 open), 1 is phase 1/phase 2 (0 open), 9 are phase 2 (9 open), and 2 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in multiple myeloma trials with MECOM mutations as inclusion criteria [3].
MET +
MET is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain MET status and multiple myeloma as inclusion criteria, 3 are phase 2 (3 open) [3].
Nivolumab, palbociclib, and dasatinib are the most frequent therapies in multiple myeloma trials with MET mutations as inclusion criteria [3].
MLF1 +
MLF1 is an inclusion eligibility criterion in 5 clinical trials for multiple myeloma, of which 5 are open and 0 are closed. Of the trials that contain MLF1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (4 open) [3].
Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in multiple myeloma trials with MLF1 mutations as inclusion criteria [3].
MLLT1 +
MLLT1 is an inclusion eligibility criterion in 15 clinical trials for multiple myeloma, of which 13 are open and 2 are closed. Of the trials that contain MLLT1 status and multiple myeloma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), 8 are phase 2 (8 open), and 2 are no phase specified (2 open) [3].
Cyclophosphamide, fludarabine, and total-body irradiation are the most frequent therapies in multiple myeloma trials with MLLT1 mutations as inclusion criteria [3].
MLLT10 +
MLLT10 is an inclusion eligibility criterion in 15 clinical trials for multiple myeloma, of which 13 are open and 2 are closed. Of the trials that contain MLLT10 status and multiple myeloma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), 8 are phase 2 (8 open), and 2 are no phase specified (2 open) [3].
Cyclophosphamide, fludarabine, and total-body irradiation are the most frequent therapies in multiple myeloma trials with MLLT10 mutations as inclusion criteria [3].
MLLT3 +
MLLT3 is an inclusion eligibility criterion in 15 clinical trials for multiple myeloma, of which 13 are open and 2 are closed. Of the trials that contain MLLT3 status and multiple myeloma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), 8 are phase 2 (8 open), and 2 are no phase specified (2 open) [3].
Cyclophosphamide, fludarabine, and total-body irradiation are the most frequent therapies in multiple myeloma trials with MLLT3 mutations as inclusion criteria [3].
MLLT4 +
MLLT4 is an inclusion eligibility criterion in 15 clinical trials for multiple myeloma, of which 13 are open and 2 are closed. Of the trials that contain MLLT4 status and multiple myeloma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), 8 are phase 2 (8 open), and 2 are no phase specified (2 open) [3].
Cyclophosphamide, fludarabine, and total-body irradiation are the most frequent therapies in multiple myeloma trials with MLLT4 mutations as inclusion criteria [3].
MPL +
MPL is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MPL status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Allogeneic hematopoietic stem cell transplantation, busulfan, and cyclophosphamide are the most frequent therapies in multiple myeloma trials with MPL mutations as inclusion criteria [3].
MRE11A +
MRE11A is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with MRE11A mutations as inclusion criteria [3].
MTOR +
MTOR is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain MTOR status and multiple myeloma as inclusion criteria, 3 are phase 2 (3 open) [3].
Nivolumab, palbociclib, and dasatinib are the most frequent therapies in multiple myeloma trials with MTOR mutations as inclusion criteria [3].
MYC +
MYC is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 2 are open and 1 is closed. Of the trials that contain MYC status and multiple myeloma as inclusion criteria, 3 are phase 1 (2 open) [3].
Bet inhibitor gsk525762, mcl-1 inhibitor mik665, and autologous hematopoietic stem cell transplatation are the most frequent therapies in multiple myeloma trials with MYC mutations as inclusion criteria [3].
MYH11 +
MYH11 is an inclusion eligibility criterion in 5 clinical trials for multiple myeloma, of which 3 are open and 2 are closed. Of the trials that contain MYH11 status and multiple myeloma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), 1 is phase 2 (1 open), and 1 is no phase specified (1 open) [3].
Cyclophosphamide, fludarabine, and total-body irradiation are the most frequent therapies in multiple myeloma trials with MYH11 mutations as inclusion criteria [3].
NBN +
NBN is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with NBN mutations as inclusion criteria [3].
NF1 +
NF1 is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain NF1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].
Vismodegib, sunitinib, and nivolumab are the most frequent therapies in multiple myeloma trials with NF1 mutations as inclusion criteria [3].
NF2 +
NF2 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain NF2 status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
Vismodegib, pertuzumab, and nivolumab are the most frequent therapies in multiple myeloma trials with NF2 mutations as inclusion criteria [3].
NPM1 +
NPM1 is an inclusion eligibility criterion in 5 clinical trials for multiple myeloma, of which 5 are open and 0 are closed. Of the trials that contain NPM1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (4 open) [3].
Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in multiple myeloma trials with NPM1 mutations as inclusion criteria [3].
NRAS +
NRAS is an inclusion eligibility criterion in 6 clinical trials for multiple myeloma, of which 5 are open and 1 is closed. Of the trials that contain NRAS status and multiple myeloma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [3].
Trametinib, erdafitinib, and dabrafenib are the most frequent therapies in multiple myeloma trials with NRAS mutations as inclusion criteria [3].
NTRK1 +
NTRK1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Azd4547, erdafitinib, and trastuzumab emtansine are the most frequent therapies in multiple myeloma trials with NTRK1 mutations as inclusion criteria [3].
NTRK2 +
NTRK2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Azd4547, erdafitinib, and trastuzumab emtansine are the most frequent therapies in multiple myeloma trials with NTRK2 mutations as inclusion criteria [3].
NTRK3 +
NTRK3 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain NTRK3 status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
Vismodegib, pertuzumab, and nivolumab are the most frequent therapies in multiple myeloma trials with NTRK3 mutations as inclusion criteria [3].
NUP214 +
NUP214 is an inclusion eligibility criterion in 16 clinical trials for multiple myeloma, of which 14 are open and 2 are closed. Of the trials that contain NUP214 status and multiple myeloma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), 9 are phase 2 (9 open), and 2 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in multiple myeloma trials with NUP214 mutations as inclusion criteria [3].
PALB2 +
PALB2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with PALB2 mutations as inclusion criteria [3].
PBX1 +
PBX1 is an inclusion eligibility criterion in 10 clinical trials for multiple myeloma, of which 10 are open and 0 are closed. Of the trials that contain PBX1 status and multiple myeloma as inclusion criteria, 2 are phase 1 (2 open), 7 are phase 2 (7 open), and 1 is no phase specified (1 open) [3].
Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in multiple myeloma trials with PBX1 mutations as inclusion criteria [3].
PDGFRA +
PDGFRA is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain PDGFRA status and multiple myeloma as inclusion criteria, 3 are phase 2 (3 open) [3].
Palbociclib, vemurafenib, and cobimetinib are the most frequent therapies in multiple myeloma trials with PDGFRA mutations as inclusion criteria [3].
PDGFRB +
PDGFRB is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain PDGFRB status and multiple myeloma as inclusion criteria, 3 are phase 2 (3 open) [3].
Palbociclib, vemurafenib, and cobimetinib are the most frequent therapies in multiple myeloma trials with PDGFRB mutations as inclusion criteria [3].
PIK3CA +
PIK3CA is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CA status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
Vismodegib, pertuzumab, and nivolumab are the most frequent therapies in multiple myeloma trials with PIK3CA mutations as inclusion criteria [3].
PIK3R1 +
PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with PIK3R1 mutations as inclusion criteria [3].
POLD1 +
POLD1 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain POLD1 status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
Olaparib, vemurafenib, and cobimetinib are the most frequent therapies in multiple myeloma trials with POLD1 mutations as inclusion criteria [3].
POLE +
POLE is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain POLE status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
Olaparib, vemurafenib, and cobimetinib are the most frequent therapies in multiple myeloma trials with POLE mutations as inclusion criteria [3].
PTCH1 +
PTCH1 is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain PTCH1 status and multiple myeloma as inclusion criteria, 3 are phase 2 (3 open) [3].
Nivolumab, palbociclib, and dasatinib are the most frequent therapies in multiple myeloma trials with PTCH1 mutations as inclusion criteria [3].
PTEN +
PTEN is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
Vismodegib, pertuzumab, and nivolumab are the most frequent therapies in multiple myeloma trials with PTEN mutations as inclusion criteria [3].
RAD50 +
RAD50 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with RAD50 mutations as inclusion criteria [3].
RAD51 +
RAD51 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with RAD51 mutations as inclusion criteria [3].
RAD51B +
RAD51B is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with RAD51B mutations as inclusion criteria [3].
RAD51C +
RAD51C is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with RAD51C mutations as inclusion criteria [3].
RAD51D +
RAD51D is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with RAD51D mutations as inclusion criteria [3].
RAF1 +
RAF1 is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain RAF1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
Raf/mek serine/threonine kinase inhibitor ro5126766, palbociclib, and trastuzumab are the most frequent therapies in multiple myeloma trials with RAF1 mutations as inclusion criteria [3].
RET +
RET is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain RET status and multiple myeloma as inclusion criteria, 3 are phase 2 (3 open) [3].
Palbociclib, vemurafenib, and cobimetinib are the most frequent therapies in multiple myeloma trials with RET mutations as inclusion criteria [3].
RHEB +
RHEB is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RHEB status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with RHEB mutations as inclusion criteria [3].
ROS1 +
ROS1 is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain ROS1 status and multiple myeloma as inclusion criteria, 3 are phase 2 (3 open) [3].
Nivolumab, palbociclib, and dasatinib are the most frequent therapies in multiple myeloma trials with ROS1 mutations as inclusion criteria [3].
RPN1 +
RPN1 is an inclusion eligibility criterion in 17 clinical trials for multiple myeloma, of which 15 are open and 2 are closed. Of the trials that contain RPN1 status and multiple myeloma as inclusion criteria, 5 are phase 1 (4 open), 1 is phase 1/phase 2 (0 open), 9 are phase 2 (9 open), and 2 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in multiple myeloma trials with RPN1 mutations as inclusion criteria [3].
RUNX1 +
RUNX1 is an inclusion eligibility criterion in 6 clinical trials for multiple myeloma, of which 4 are open and 2 are closed. Of the trials that contain RUNX1 status and multiple myeloma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), 2 are phase 2 (2 open), and 1 is no phase specified (1 open) [3].
Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in multiple myeloma trials with RUNX1 mutations as inclusion criteria [3].
RUNX1T1 +
RUNX1T1 is an inclusion eligibility criterion in 5 clinical trials for multiple myeloma, of which 3 are open and 2 are closed. Of the trials that contain RUNX1T1 status and multiple myeloma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), 1 is phase 2 (1 open), and 1 is no phase specified (1 open) [3].
Cyclophosphamide, fludarabine, and total-body irradiation are the most frequent therapies in multiple myeloma trials with RUNX1T1 mutations as inclusion criteria [3].
SF3B1 +
SF3B1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Mln9708, allogeneic hematopoietic stem cell transplantation, and cyclophosphamide are the most frequent therapies in multiple myeloma trials with SF3B1 mutations as inclusion criteria [3].
SLX4 +
SLX4 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with SLX4 mutations as inclusion criteria [3].
SMO +
SMO is an inclusion eligibility criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain SMO status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [3].
Vismodegib, pertuzumab, and nivolumab are the most frequent therapies in multiple myeloma trials with SMO mutations as inclusion criteria [3].
SRC +
SRC is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain SRC status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].
Nivolumab, pertuzumab, and vemurafenib are the most frequent therapies in multiple myeloma trials with SRC mutations as inclusion criteria [3].
SRSF2 +
SRSF2 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains SRSF2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Allogeneic hematopoietic stem cell transplantation, busulfan, and cyclophosphamide are the most frequent therapies in multiple myeloma trials with SRSF2 mutations as inclusion criteria [3].
STK11 +
STK11 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with STK11 mutations as inclusion criteria [3].
TCF3 +
TCF3 is an inclusion eligibility criterion in 10 clinical trials for multiple myeloma, of which 10 are open and 0 are closed. Of the trials that contain TCF3 status and multiple myeloma as inclusion criteria, 2 are phase 1 (2 open), 7 are phase 2 (7 open), and 1 is no phase specified (1 open) [3].
Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in multiple myeloma trials with TCF3 mutations as inclusion criteria [3].
TP53 +
TP53 is an inclusion eligibility criterion in 21 clinical trials for multiple myeloma, of which 18 are open and 3 are closed. Of the trials that contain TP53 status and multiple myeloma as inclusion criteria, 5 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 11 are phase 2 (11 open), and 2 are no phase specified (2 open) [3].
Fludarabine, cyclophosphamide, and total-body irradiation are the most frequent therapies in multiple myeloma trials with TP53 mutations as inclusion criteria [3].
TSC1 +
TSC1 is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain TSC1 status and multiple myeloma as inclusion criteria, 3 are phase 2 (3 open) [3].
Nivolumab, palbociclib, and dasatinib are the most frequent therapies in multiple myeloma trials with TSC1 mutations as inclusion criteria [3].
TSC2 +
TSC2 is an inclusion eligibility criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain TSC2 status and multiple myeloma as inclusion criteria, 3 are phase 2 (3 open) [3].
Nivolumab, palbociclib, and dasatinib are the most frequent therapies in multiple myeloma trials with TSC2 mutations as inclusion criteria [3].
VHL +
VHL is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Axitinib, bosutinib, and cobimetinib are the most frequent therapies in multiple myeloma trials with VHL mutations as inclusion criteria [3].
WHSC1 +
WHSC1 is an inclusion eligibility criterion in 10 clinical trials for multiple myeloma, of which 9 are open and 1 is closed. Of the trials that contain WHSC1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 7 are phase 2 (7 open) [3].
Melphalan, lenalidomide, and cyclophosphamide are the most frequent therapies in multiple myeloma trials with WHSC1 mutations as inclusion criteria [3].
YES1 +
YES1 is an inclusion eligibility criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains YES1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [3].
Cetuximab, cobimetinib, and crizotinib are the most frequent therapies in multiple myeloma trials with YES1 mutations as inclusion criteria [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
